TICKERNERD
Menu
BYSIBYSIHealthcare · Biotechnology

BYSI Stock Forecast: BeyondSpring, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.64
−6.86% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 6 Oct 2026 — in the weakest quartile.

Market cap
$28.5M
Ticker Nerd rank
19 / 100
Median analyst target
—
Analysts covering
2
Revenue$0.0
Operating income−$1.7M
Net income−$5.7M
Free cash flow−$3.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.3%
1M
+4.3%
YTD
−60.5%
1Y
−64.1%
From 52W high
−72.6%
From 52W low
+6.9%
$0.60
$2.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BYSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BeyondSpring, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Issuance
56
Accruals
54
Volatility
50
Momentum
34
Revisions
25
Value
22
Quality
10
Growth
8

Size (86): Smaller than most of the companies we track.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BYSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26BYSI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 May 2023BairdMaintainsOutperform$4.00 → $1.25
2 Dec 2021B of A SecuritiesDowngradeUnderperform—
2 Dec 2021JefferiesDowngradeHold—
1 Dec 2021HC Wainwright & Co.DowngradeNeutral—
20 Sept 2021HC Wainwright & Co.MaintainsBuy—
9 Sept 2021BairdInitiatesOutperform—
4 Aug 2021HC Wainwright & Co.UpgradeBuy—
5 Apr 2021HC Wainwright & Co.DowngradeNeutral—
11 Jan 2021B of A SecuritiesInitiatesBuy—
29 Dec 2020Evercore ISI GroupInitiatesOutperform—
15 June 2020HC Wainwright & Co.MaintainsBuy—
30 Mar 2020HC Wainwright & Co.MaintainsBuy—
7 Feb 2020JefferiesInitiatesBuy—
10 Jan 2020NomuraInitiatesBuy—
10 Jan 2020Nomura InstinetInitiatesBuy—
3 Dec 2019William BlairInitiatesOutperform—
22 June 2018Maxim GroupMaintainsBuy—
4 Apr 2017Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BYSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BYSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, BeyondSpring, Inc. returned −64.1% against +17.4% for the S&P 500, dividends included.

BYSI vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26BYSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BYSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

BeyondSpring, Inc. (BYSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−34.7×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
−0.8×

Cheaper than 94% of US stocks

EV / EBITDA
−2.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
4.2%

Higher than 52% of US stocks

Return on assets
−22.9%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BeyondSpring, Inc. (BYSI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BeyondSpring, Inc. has a market value of $28.5M and an enterprise value of $21.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$23.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$16.7M.

  • Shares outstanding: 41.1M.

  • Trailing P/E: −34.7×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BeyondSpring, Inc. employs 44 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

BYSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BYSIBeyondSpring, Inc.$28.5M
19
IGCIGC Pharma, Inc.$28.9M
6
MCRBSeres Therapeutics, Inc.$27.8M
56
ATYRaTyr Pharma, Inc.$27.8M
53
GRDXGridAI Technologies Corp.$29.5M
19
CNTXContext Therapeutics, Inc.$29.6M
26
RNAZTransCode Therapeutics, Inc.$30.1M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BeyondSpring, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BYSI news & analysis

BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript

Seeking Alpha · 29 Sept 2026positive

BeyondSpring Inc. (BYSI) discussed its FDA Fast Track designation and a strategic transaction for Plinabulin in post-ICI non-squamous non-small cell lung cancer (NSCLC) in a transcript of company remarks.

Why it matters — A BYSI watcher would care because FDA Fast Track status and a strategic transaction could represent meaningful progress for Plinabulin's development in this non-squamous NSCLC indication.

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

GlobeNewsWire · 29 Sept 2026positive

BeyondSpring announced that the FDA granted Fast Track designation to Plinabulin combined with docetaxel for treating advanced or metastatic non-squamous non-small cell lung cancer in patients who progressed after prior anti-PD-(L)1 antibody and platinum-based chemotherapy. This population is being studied in the company's global Phase 3 DUBLIN-4 trial, which the company says it is advancing toward a planned interim analysis.

Why it matters — FDA Fast Track designation may accelerate development and review of Plinabulin, a key pipeline candidate, as BeyondSpring works toward the interim analysis of its DUBLIN-4 trial.

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 14 Aug 2026positive

BeyondSpring reported its second-quarter 2026 financial results and provided a corporate update. The update highlights ASCO 2026 data demonstrating a long-term survival benefit of Plinabulin/Docetaxel and Pembrolizumab in metastatic non-small cell lung cancer following progression on first-line immune checkpoint inhibitor therapy.

Why it matters — BYSI watchers would care because the ASCO 2026 data provides encouraging evidence of a long-term survival benefit for Plinabulin-based combinations in a difficult-to-treat NSCLC patient population.

FAQ

Frequently asked questions about BYSI stock

Is BYSI stock a buy right now?

Of the 2 analysts covering BeyondSpring, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BeyondSpring, Inc. 19 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BYSI?

As at 6 Oct 2026, BeyondSpring, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

What is the BYSI stock forecast for 2030?

No analyst covering BeyondSpring, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYSI are extrapolating price history, which says nothing about the business.

How has BYSI stock performed over the past year?

BeyondSpring, Inc. returned -64.1% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BeyondSpring, Inc. do?

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care.

What is the latest news on BYSI?

The most recent item we track (Seeking Alpha, 29 Sept 2026): "BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript". BeyondSpring Inc. (BYSI) discussed its FDA Fast Track designation and a strategic transaction for Plinabulin in post-ICI non-squamous non-small cell lung cancer (NSCLC) in a transcript of company remarks.

Company

About BeyondSpring, Inc.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment. BeyondSpring also operates a TPD platform that supports the discovery and development of therapeutic agents and new chemical entities. Its work is directed at addressing unmet needs in cancer care through targeted drug development and clinical research. Headquartered in Florham Park, New Jersey, BeyondSpring Inc. plays a specialized role in the biotechnology market as a research-driven company advancing late-stage and early-stage therapeutic candidates.

CEO Dr. Lan Huang Ph.D. · 44 employees · United States · https://beyondspringpharma.com